分析阿帕替尼联合顺铂腹腔灌注治疗卵巢癌恶性腹腔积液的有效性
|
摘要
目的:探究卵巢癌恶性腹腔积液患者应用阿帕替尼联合顺铂治疗的效果。方法:随机抽取笔者所在医院2018年1月-2019年1月进行治疗的卵巢癌恶性腹腔积液患者60例为研究对象,实施顺铂治疗的30例为对照组,实施阿帕替尼联合顺铂治疗的30例为研究组,对比两组治疗效果、治疗前后腹水VEGF及不良反应发生情况。结果:研究组治疗总有效率明显高于对照组,差异有统计学意义(P<0.05)。治疗前两组腹水VEGF比较,差异无统计学意义(P>0.05);治疗后两组腹水VEGF均较治疗前有所改善,且研究组较对照组改善更显著,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:卵巢癌恶性腹腔积液患者应用阿帕替尼联合顺铂的治疗效果明显好于单独使用顺铂治疗,能够在提升治疗效果前提下确保治疗的安全性,值得推广应用。
Objective:To explore the efficacy of Apatinib combined with Cisplatin in the treatment of patients with malignant peritoneal effusion of ovarian cancer.Method:A total of 60 patients with malignant peritoneal effusion of ovarian cancer treated in our hospital from January 2018 to January 2019 were randomly selected as the research object.30 patients were treated with Aisplatin as control group,and 30 patients treated with Apatinib combined with Cisplatin as the research group,The therapeutic effect,ascites VEGF and adverse reactions before and after the treatment were compared between the two groups.Result:The total effective rate of the research group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in ascites VEGF between the two groups before treatment(P>0.05).After treatment,the improvement of ascites VEGF in both groups was better than that before treatment,and the improvement in the research group was more significant than that in the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The efficacy of Apatinib combined with Cisplatin in patients with malignant peritoneal effusion of ovarian cancer is significantly better than that of Cisplatin alone,which can ensure the safety of treatment under the premise of improving the therapeutic effect,and is worthy of promotion and application.
Objective:To explore the efficacy of Apatinib combined with Cisplatin in the treatment of patients with malignant peritoneal effusion of ovarian cancer.Method:A total of 60 patients with malignant peritoneal effusion of ovarian cancer treated in our hospital from January 2018 to January 2019 were randomly selected as the research object.30 patients were treated with Aisplatin as control group,and 30 patients treated with Apatinib combined with Cisplatin as the research group,The therapeutic effect,ascites VEGF and adverse reactions before and after the treatment were compared between the two groups.Result:The total effective rate of the research group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in ascites VEGF between the two groups before treatment(P>0.05).After treatment,the improvement of ascites VEGF in both groups was better than that before treatment,and the improvement in the research group was more significant than that in the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The efficacy of Apatinib combined with Cisplatin in patients with malignant peritoneal effusion of ovarian cancer is significantly better than that of Cisplatin alone,which can ensure the safety of treatment under the premise of improving the therapeutic effect,and is worthy of promotion and application.
引文
[1]黎晓鹃,张化芝,赵世义.阿帕替尼联合顺铂治疗卵巢癌患者恶性腹腔积液的疗效观察[J/OL].临床医药文献电子杂志,2017,4(31):6105.
[2]赵攀攀,邱海峰,苑中甫,等.阿帕替尼与脂质体阿霉素联合治疗复发性卵巢癌的短期疗效和安全性[J].现代妇产科进展,2017,26(12):921-923.
[3]李琪,赵峻峰,史晓宇,等.阿帕替尼联合化疗用于二线治疗失败晚期卵巢癌的临床观察[J].河北医科大学学报,2017,38(12):1384-1387.
[4]安改丽,李旭,黄尚科,等.阿帕替尼联合顺铂对食管癌ECA109细胞抑制作用及机制探讨[J].陕西医学杂志,2017,46(2):148-151.
[5]高世乐,芦东徽,刘美琴.阿帕替尼与多西他赛联合顺铂化疗对晚期胃癌的近期疗效及毒副反应[J].中国肿瘤生物治疗杂志,2018,25(11):1131-1134.
[6]李元元,刘珏,周庆,等.阿帕替尼致2例严重不良反应分析[J].中国药师,2017,20(11):2037-2038.
[7]李春杏,高玲燕,郑丽.阿帕替尼对晚期实体恶性肿瘤疗效和安全性Meta分析[J].中华肿瘤防治杂志,2018,25(15):69-78.
[8]赖章超,梁仁佩,吴清木,等.甲磺酸阿帕替尼对二线治疗失败的晚期卵巢癌的近期疗效观察[J].实用肿瘤杂志,2018,33(4):26-29.
[9]程谟朝,徐姝丽,姚洪莹,等.小剂量阿帕替尼联合多西他赛对照多西他赛治疗二线及二线以上卵巢癌的疗效及安全性[J].中国医药指南,2018,16(13):211-212.
[10]杨武,程明,于立江.多西他赛联合阿帕替尼对晚期食管癌患者免疫功能及生活质量影响[J].临床军医杂志,2018,46(11):110-111.
[11]赵鑫.阿帕替尼联合紫杉醇治疗晚期化疗耐药HER-2阴性胃癌的临床效果评价[J].中外医疗,2017,36(35):127-129.
[12]耿海燕.甲磺酸阿帕替尼治疗晚期卵巢癌的疗效评价及其对血清HE4、CA 125及CA 199的影响[J].中国临床实用医学,2017,8(2):73-74.
[13]徐云莹,向军英,刘哲,等.阿帕替尼结合顺铂对结肠癌细胞的抑制作用及其分子机制分析[J].临床和实验医学杂志,2018,17,267(11):87-90.
[2]赵攀攀,邱海峰,苑中甫,等.阿帕替尼与脂质体阿霉素联合治疗复发性卵巢癌的短期疗效和安全性[J].现代妇产科进展,2017,26(12):921-923.
[3]李琪,赵峻峰,史晓宇,等.阿帕替尼联合化疗用于二线治疗失败晚期卵巢癌的临床观察[J].河北医科大学学报,2017,38(12):1384-1387.
[4]安改丽,李旭,黄尚科,等.阿帕替尼联合顺铂对食管癌ECA109细胞抑制作用及机制探讨[J].陕西医学杂志,2017,46(2):148-151.
[5]高世乐,芦东徽,刘美琴.阿帕替尼与多西他赛联合顺铂化疗对晚期胃癌的近期疗效及毒副反应[J].中国肿瘤生物治疗杂志,2018,25(11):1131-1134.
[6]李元元,刘珏,周庆,等.阿帕替尼致2例严重不良反应分析[J].中国药师,2017,20(11):2037-2038.
[7]李春杏,高玲燕,郑丽.阿帕替尼对晚期实体恶性肿瘤疗效和安全性Meta分析[J].中华肿瘤防治杂志,2018,25(15):69-78.
[8]赖章超,梁仁佩,吴清木,等.甲磺酸阿帕替尼对二线治疗失败的晚期卵巢癌的近期疗效观察[J].实用肿瘤杂志,2018,33(4):26-29.
[9]程谟朝,徐姝丽,姚洪莹,等.小剂量阿帕替尼联合多西他赛对照多西他赛治疗二线及二线以上卵巢癌的疗效及安全性[J].中国医药指南,2018,16(13):211-212.
[10]杨武,程明,于立江.多西他赛联合阿帕替尼对晚期食管癌患者免疫功能及生活质量影响[J].临床军医杂志,2018,46(11):110-111.
[11]赵鑫.阿帕替尼联合紫杉醇治疗晚期化疗耐药HER-2阴性胃癌的临床效果评价[J].中外医疗,2017,36(35):127-129.
[12]耿海燕.甲磺酸阿帕替尼治疗晚期卵巢癌的疗效评价及其对血清HE4、CA 125及CA 199的影响[J].中国临床实用医学,2017,8(2):73-74.
[13]徐云莹,向军英,刘哲,等.阿帕替尼结合顺铂对结肠癌细胞的抑制作用及其分子机制分析[J].临床和实验医学杂志,2018,17,267(11):87-90.